The medical community has seen an explosive rise in the utilization of implantable mechanical circulatory support devices for late-stage cardiomyopathy. Care for these complex patients requires a basic understanding of device physiology and potential complications. This review focuses on an algorithm that incorporates a careful clinical history and examination with diagnostic modalities for the evaluation of a patient who is failing therapy with a continuous-flow left ventricular assist device, as well as the general management and optimization of patients implanted with an artificial heart.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11897-011-0079-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Review of Cardiogenic Shock After Acute Myocardial Infarction　- Revascularization, Mechanical Circulatory Support, and Beyond.
Circ Rep
January 2025
Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine Chiba Japan.
Owing to recent advances in early reperfusion and pharmacological therapies, the prognosis of patients with acute myocardial infarction (AMI) has considerably improved over the past decades. However, the mortality rate remains high at ~40-50% after AMI when complicated by cardiogenic shock. Although immediate coronary revascularization of the infarct-related artery has been the only evidence-based treatment, temporary mechanical circulatory support with a microaxial flow pump (Impella) has become another therapeutic option supported by randomized trial data in highly selected patients.
View Article and Find Full Text PDFCase report of entrectinib associated fulminant myocarditis.
Eur Heart J Case Rep
January 2025
Department of Cardiology, York Hospital, WellSpan Health, 30 Monument Rd, York, PA 17403, USA.
Background: ROS1 tyrosine kinase inhibitors are one of the primary immunotherapies for fusion-positive cancers. Tyrosine kinase inhibitors have markedly improved outcomes for advanced cancers previously with poor prognosis. Entrectinib is an example of an ROS1 inhibitor that can be used for lung adenocarcinoma.
View Article and Find Full Text PDFHow to Manage Ventricular Arrhythmia Following Durable Left Ventricular Assist Device Implantation.
J Cardiovasc Electrophysiol
January 2025
Second Department of Internal Medicine, University of Toyama, Toyama, Japan.
Relationships between adrenal insufficiency and cardiovascular outcomes in patients with congestive heart failure.
Nutr Metab Cardiovasc Dis
December 2024
Diabetes and Endocrinology, Department of Internal Medicine, Hennepin Healthcare, Minneapolis, MN, USA.
Background And Aims: Patients with adrenal insufficiency (AI) face elevated risks during various hospitalizations including cardiovascular related admissions. Despite this, limited data exist specifically regarding congestive heart failure (CHF) in the context of AI. This investigation leveraged a comprehensive national database to examine the association between AI and cardiovascular outcomes among patients admitted with CHF.
View Article and Find Full Text PDFFrom Escalate to Elevate: A New Paradigm for Comprehensive Cardiogenic Shock Management.
Can J Cardiol
January 2025
Ted Rogers Centre for Heart Research, University Health Network, Toronto, ON, Canada; Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada. Electronic address:
Patients with cardiogenic shock (CS) present with critical hemodynamic compromise with low cardiac output (CO) resulting in end-organ dysfunction. Prognosis is closely related to the severity of shock and treatment of patients with CS is resource intensive. In this review, we consider the current treatment paradigms alongside the evidence that underpins them.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!